MedTrace Logo

The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial

NCT04364815 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2020-11-06

No results posted yet for this study

Summary

This COVID-19 pandemic warrants urgent strategies to protect people at high risk of infection, particularly the healthcare workers. Secondary prevention through post-exposure prophylaxis (PEP) and early treatment of infection are needed to prevent severe cases and cut secondary transmission. Hydroxycholoroquine (HCQ) is an inexpensive anti-malarial drug with immunomodulatory effects that are currently used as an off-label treatment for symptomatic COVID-19 patients. In vitro studies have shown that it can efficiently inhibit SARS-CoV-2 infection and has potential as a post-exposure prophylaxis drug.

Conditions

Interventions

DRUG

Hydroxychloroquine plus standard preventive measures

Hydroxychloroquine and standard preventive measures

DRUG

Placebo plus standard preventive measures

Placebo tablet plus standard preventive measures as defined by PGH-HICU

Sponsors & Collaborators

  • University of the Philippines

    lead OTHER

Principal Investigators

  • Belen L Dofitas, MD · Philippine General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-31
Primary Completion
2021-05-31
Completion
2021-05-31

Countries

  • Philippines

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04364815 on ClinicalTrials.gov